EP2968317A4 - Ciblage thérapeutique de la voie mtor dans des affections neurologiques - Google Patents

Ciblage thérapeutique de la voie mtor dans des affections neurologiques

Info

Publication number
EP2968317A4
EP2968317A4 EP14762460.5A EP14762460A EP2968317A4 EP 2968317 A4 EP2968317 A4 EP 2968317A4 EP 14762460 A EP14762460 A EP 14762460A EP 2968317 A4 EP2968317 A4 EP 2968317A4
Authority
EP
European Patent Office
Prior art keywords
neurological diseases
mtor pathway
therapeutic targeting
targeting
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP14762460.5A
Other languages
German (de)
English (en)
Other versions
EP2968317A1 (fr
Inventor
Maria Karayiorgou
Sander Markx
Joseph A Gogos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP2968317A1 publication Critical patent/EP2968317A1/fr
Publication of EP2968317A4 publication Critical patent/EP2968317A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP14762460.5A 2013-03-15 2014-03-17 Ciblage thérapeutique de la voie mtor dans des affections neurologiques Ceased EP2968317A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361852150P 2013-03-15 2013-03-15
US201361794606P 2013-03-15 2013-03-15
US201361803977P 2013-03-21 2013-03-21
US201361918307P 2013-12-19 2013-12-19
PCT/US2014/030693 WO2014145857A1 (fr) 2013-03-15 2014-03-17 Ciblage thérapeutique de la voie mtor dans des affections neurologiques

Publications (2)

Publication Number Publication Date
EP2968317A1 EP2968317A1 (fr) 2016-01-20
EP2968317A4 true EP2968317A4 (fr) 2016-12-28

Family

ID=51538117

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14762460.5A Ceased EP2968317A4 (fr) 2013-03-15 2014-03-17 Ciblage thérapeutique de la voie mtor dans des affections neurologiques

Country Status (2)

Country Link
EP (1) EP2968317A4 (fr)
WO (1) WO2014145857A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013003801A2 (fr) 2011-06-29 2013-01-03 The Trustees Of Columbia University In The City Of New York Inhibiteur de la connectivité neuronale lié à la susceptibilité à la schizophrénie et à un dysfonctionnement cognitif
CN104829610B (zh) * 2014-06-20 2017-03-15 中国科学院合肥物质科学研究院 一种新型布鲁顿酪氨酸激酶抑制剂
CN112237629A (zh) * 2019-07-16 2021-01-19 温州市中心医院 ERK/mTOR信号通路调节剂在制备改善或治疗神经发育障碍相关疾病药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062681A2 (fr) * 2008-10-30 2010-06-03 University Of South Florida Lutéoline et diosmine/diosmétine en tant que nouveaux inhibiteurs de stat3 destinés à traiter l'autisme
US20100298304A1 (en) * 2009-01-16 2010-11-25 Massachusetts Institute Of Technology Diagnosis and treatment of autism spectrum disorders
CN102488687A (zh) * 2011-12-22 2012-06-13 武汉大学 雷帕霉素在制备治疗精神分裂症中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659851C (fr) * 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited Derives de la 2-methylmorpholine pyrido-, pyrazo- et pyrimido-pyrimidine en tant qu'inhibiteurs de mtor
US20140018354A9 (en) * 2009-07-23 2014-01-16 Nathaniel Moorman Inhibitors of mtor kinase as anti-viral agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062681A2 (fr) * 2008-10-30 2010-06-03 University Of South Florida Lutéoline et diosmine/diosmétine en tant que nouveaux inhibiteurs de stat3 destinés à traiter l'autisme
US20100298304A1 (en) * 2009-01-16 2010-11-25 Massachusetts Institute Of Technology Diagnosis and treatment of autism spectrum disorders
CN102488687A (zh) * 2011-12-22 2012-06-13 武汉大学 雷帕霉素在制备治疗精神分裂症中的应用

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ATSUSHI SATO ET AL: "Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex", NATURE COMMUNICATIONS, vol. 3, 18 December 2012 (2012-12-18), United Kingdom, pages 1292, XP055320205, ISSN: 2041-1723, DOI: 10.1038/ncomms2295 *
BALLOU; LIN, J. CHEM. BIOL., vol. 1, 2008, pages 27 - 36 *
DELIA M. TALOS ET AL: "The Interaction between Early Life Epilepsy and Autistic-Like Behavioral Consequences: A Role for the Mammalian Target of Rapamycin (mTOR) Pathway", PLOS ONE, vol. 7, no. 5, 2 May 2012 (2012-05-02), pages e35885, XP055320394, DOI: 10.1371/journal.pone.0035885 *
GARCÍA-ECHEVERRÍA CARLOS: "Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 15, 2010, pages 4308 - 4312, XP028851573, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2010.05.099 *
GUERTIN, SABATINI, SCIENCE SIGNALLING, vol. 2, no. 67, PE24, 21 April 2009 (2009-04-21), pages 1 - 6 *
JULIE MEFFRE ET AL: "5-HT 6 receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia", EMBO MOLECULAR MEDICINE, vol. 4, no. 10, 1 October 2012 (2012-10-01), Weinheim, pages 1043 - 1056, XP055285724, ISSN: 1757-4676, DOI: 10.1002/emmm.201201410 *
KER YU ET AL: "Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 70, no. 2, 15 January 2010 (2010-01-15), pages 621 - 631, XP002646841, ISSN: 0008-5472, [retrieved on 20100112], DOI: 10.1158/0008-5472.CAN-09-2340 *
PETER T. TSAI ET AL: "Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice", NATURE, vol. 488, no. 7413, 1 July 2012 (2012-07-01), United Kingdom, pages 647 - 651, XP055320065, ISSN: 0028-0836, DOI: 10.1038/nature11310 *
POWELL; DELGOFFE: "The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism", IMMUNITY, vol. 33, no. 3, 1 September 2010 (2010-09-01), US, pages 301 - 311, XP055591065, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2010.09.002 *
Q. LIU ET AL: "Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR", CANCER RESEARCH, vol. 73, no. 8, 22 February 2013 (2013-02-22), US, pages 2574 - 2586, XP055286271, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-12-1702 *
SAXTON; SABATINI, CELL, vol. 168, September 2017 (2017-09-01), pages 960 - 974 *
See also references of WO2014145857A1 *
THEOHARIDES THEOHARIS C: "Is a Subtype of Autism an Allergy of the Brain?", CLINICAL THERAPEUTICS, EXCERPTA MEDICA, PRINCETON, NJ, US, vol. 35, no. 5, 27 April 2013 (2013-04-27), pages 584 - 591, XP028543857, ISSN: 0149-2918, DOI: 10.1016/J.CLINTHERA.2013.04.009 *
WANDER ET AL., J. CLINICAL INVENTIGATION, vol. 121, 2011, pages 1231 - 1241 *
ZHOU MIOU ET AL: "mTOR Inhibition Ameliorates Cognitive and Affective Deficits Caused by Disc1 Knockdown in Adult-Born Dentate Granule Neurons", NEURON, CELL PRESS, US, vol. 77, no. 4, 20 February 2013 (2013-02-20), pages 647 - 654, XP028983424, ISSN: 0896-6273, DOI: 10.1016/J.NEURON.2012.12.033 *

Also Published As

Publication number Publication date
WO2014145857A1 (fr) 2014-09-18
EP2968317A1 (fr) 2016-01-20

Similar Documents

Publication Publication Date Title
IL274646A (en) Integrated continuous production of medicinal substances from medical protein
CY2019033I2 (el) Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων
IL269511A (en) New therapeutic approaches for treating parkinson's disease
HUE039864T2 (hu) Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
HRP20182069T1 (hr) Farmaceutski pripravci za liječenje alzheimerove bolesti
PT2882441T (pt) Tratamento de doenças associadas à imunidade e inflamatórias
EP2838909A4 (fr) Agents thérapeutiques ciblés
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
LT2796132T (lt) Neurologinių sutrikimų terapija baklofeno ir akamprosato pagrindu
EP2819703A4 (fr) Traitement de la douleur
EP2906208A4 (fr) Traitement thérapeutique
IL229017B (en) Oxidative retinal diseases
IL233313A0 (en) Composition of novel carbohydrate drug for treatment of human diseases
PT2872497T (pt) Derivados de cromanilo para o tratamento de doenças mitocondriais
EP2872120A4 (fr) Nanoparticules thérapeutiques ciblées
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
IL233639B (en) Compositions and methods for the treatment of hepatic diseases and disorders
IL235768A0 (en) Pharmaceutical compositions and treatment of mastitis
PL2922576T3 (pl) Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej
EP2912186A4 (fr) Traitement ciblant les plaquettes
IL234606B (en) Novel methods and composition for treatment of disease
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
SMT201700103B (it) Bersaglio terapeutico e diagnostico
IL235874A0 (en) Treatment of ocular inflammatory diseases by laquinimod

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/497 20060101AFI20160727BHEP

Ipc: A61K 31/519 20060101ALI20160727BHEP

Ipc: A61P 25/00 20060101ALN20160727BHEP

Ipc: A61K 31/4745 20060101ALI20160727BHEP

Ipc: C07D 471/04 20060101ALI20160727BHEP

Ipc: A61P 25/24 20060101ALN20160727BHEP

Ipc: A61K 31/5377 20060101ALI20160727BHEP

Ipc: A61P 25/18 20060101ALN20160727BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20161128

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/24 20060101ALN20161122BHEP

Ipc: A61K 31/497 20060101AFI20161122BHEP

Ipc: C07D 471/04 20060101ALI20161122BHEP

Ipc: A61P 25/00 20060101ALN20161122BHEP

Ipc: A61K 31/5377 20060101ALI20161122BHEP

Ipc: A61K 31/4745 20060101ALI20161122BHEP

Ipc: A61K 31/519 20060101ALI20161122BHEP

Ipc: A61P 25/18 20060101ALN20161122BHEP

17Q First examination report despatched

Effective date: 20180810

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20201009